Capecitabine is a chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Cancer is the second leading cause of death worldwide–around 9.6 million deaths every year are caused by cancer, WHO. In addition, more than 70% of deaths occur in low and middle-income countries. Thereon, with the increasing prevalence of cancer incidences worldwide, the overall demand for chemotherapeutic agents has increased significantly. Capecitabine has huge potential to meet the increasing need for new agents, which can more aggressively treat breast cancer in the earlier stages.
Global capecitabine market accounted for around USD 1,652 million in 2017 and is expected to grow at a healthy CAGR during the forecast period, 2023–2031.
Global capecitabine market is segmented
By application and drug formulation.
By application, the market is segmented into colon cancer, rectal cancer, breast cancer, gastric cancer, and others.
By drug formulation, capecitabine market is segmented into tablets and capsules. Tablets segment is expected to dominate due to high production by manufacturers.
Geographically, the global capecitabine market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA).
The Americas is projected to dominate the global capecitabine market due to increasing prevalence of cancer in the region. Around 1,735,350 new cases of cancer were reported in 2018, National Cancer Institute. In line with this, many players are engaged in developing better treatment options. For instance, Puma Biotechnology has received positive results from the company’s lead drug Neratinib used in breast cancer. The treatment involves combination therapy with capecitabine.
Europe is the second largest market globally. This can be attributed to rising incidences of cancers, which is the second leading cause of death and morbidity in Europe. Around 3.7 million new cases occur each year in Europe, WHO. Novel therapies are the need of the hour in the region. Around USD 1.5 billion has been invested by the European government on cancer research, European Commission.
Asia Pacific is expected to witness significant growth. The region houses huge tobacco consuming population, killing more than 2.3 million every year. However, lack of awareness in the region is leading to delay in the detection of cancer. In 2018, most of the new cancer cases were diagnosed from Eastern Asia around 5.6 million, according to Cancer Organization. To educate people about symptoms and diagnosis of cancer, governments are conducting many programs and screening drives.
MEA is expected to witness steady growth as a result of growing burden of cancer on the Middle East & Africa region due to poor healthcare facilities.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
By Drug Formulation